New: Biosimilars strategies introduced.
Close
Valuable and timely information on drug therapy issues impacting today's health care and pharmacy environment.
On January 21, 2022, AbbVie announced the FDA approval of Skyrizi (risankizumab-rzaa), for the treatment of active psoriatic arthritis in adults.
Download PDF
Return to publications
